Mereo BioPharma sets up shop with Novartis spin-offs
This article was originally published in Scrip
Executive Summary
New UK specialist biotech company Mereo BioPharma is on the look-out for a handful of further promising products to add to the three clinical-stage products it has just acquired from Novartis, according to company CEO Denise Scots-Knight.